Non-small cell lung cancer (NSCLC) is one of the most common types of cancer in the world and has a 5-year survival rate of ~20%. Immunotherapies have shown promising results leading to durable responses, however, they are only effective for a subset of patients. To determine the best therapeutic approach, a thorough and in-depth profiling of the tumour microenvironment (TME) is required. The TME is a complex network of cell types that form an interconnected network, promoting tumour cell initiation, growth and dissemination. The stroma, immune cells and endothelial cells that comprise the TME generate a plethora of cytotoxic or cytoprotective signalling pathways. In this review, we discuss immunotherapeutic targets in NSCLC tumours and how the TME may influence patients' response to immunotherapy.
Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-No Derivative Works 4.0 International License.
Sadeghirad, Habib; Bahrami, Tayyeb; Layeghi, Sepideh M.; Yousefi, Hassan; Rezaei, Meysam; Hosseini-Fard, Seyed R.; Radfar, Payar; Warkiani, Majid E.; O'Byrne, Ken; and Kulasinghe, Arutha, "Immunotherapeutic Targets In Non-small Cell Lung Cancer" (2023). School of Medicine Faculty Publications. 988.